Cytokinetics, Incorporated (CYTK) vs GRAIL Inc. (GRAL)

A side-by-side comparison of Cytokinetics, Incorporated and GRAIL Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

CYTK

Cytokinetics, Incorporated

$7.61B

$61.14HealthcareDelayed quote: Oct 6, 2026, 3:05 PM EDT

GRAL

GRAIL Inc.

$5.88B

$136.91HealthcareDelayed quote: Oct 6, 2026, 3:05 PM EDT

Total return — CYTK vs GRAL

growth of $100 · dividends reinvested · last 2y

CYTK +16.0% (+7.7%/yr)GRAL +1028.0% (+235.9%/yr)GRAL compounded faster over this window

Log scale — wide-divergence pair

CYTK GRAL

CYTK vs GRAL: by the numbers

•CYTK is the larger company ($7.61B vs $5.88B market cap).
•Both run net losses; GRAL's is the smaller (-236.95% vs -1259.87% net margin).

Metrics side by side

Valuation

Metric	CYTK	GRAL
P/S ratio	107.21	35.55
P/B ratio	N/A	2.31

Profitability

Metric	CYTK	GRAL
Gross margin	84.97%	-42.52%
Operating margin	-695.44%	-362.95%
Net margin	-1259.87%	-236.95%
ROE	N/A	-15.40%
ROIC	-39.80%	-20.26%

Growth (annualized)

Metric	CYTK	GRAL
Revenue CAGR (5Y)	4.19%	N/A
Total return CAGR (5Y)	11.24%	N/A

Go deeper

Full CYTK analysis Full GRAL analysis Interactive comparison tool

Dig into the metrics

Cytokinetics ROE GRAIL ROE Cytokinetics operating margin GRAIL operating margin Cytokinetics revenue growth GRAIL revenue growth Cytokinetics free cash flow GRAIL free cash flow

Cytokinetics & GRAIL appear in these rankings

Highest 10-Year Total Return Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.